Form 4: Revvity CFO Granted Stock Options

Revvity's Chief Financial Officer, Maxwell Krakowiak, was granted 44,446 non-qualified stock options with an exercise price of $90.465, vesting over three years.

Summary

• Maxwell Krakowiak, Senior Vice President and Chief Financial Officer of Revvity, Inc. (RVTY), was granted 44,446 non-qualified stock options.
• The options have an exercise price of $90.465 per share.
• These options are scheduled to fully vest on the third anniversary of the grant date, which is August 15, 2028.
• The options have a 7-year term and will expire on August 15, 2032.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally positive as it aligns management's interests with long-term shareholder value, though it's a routine compensation event.

Positives

• The grant of stock options aligns the interests of the Chief Financial Officer with shareholders, incentivizing long-term company performance.

Future Outlook

The options are structured to incentivize long-term performance, with full vesting scheduled for August 15, 2028, aligning the CFO's compensation with future stock price appreciation.

Management Comments

• Maxwell Krakowiak holds the position of Senior Vice President and Chief Financial Officer.

Industry Context

The grant of stock options to key executives like the CFO is a common practice in the industry to align management incentives with shareholder value creation and retain talent.

Comparison to Industry Standards

• The grant of non-qualified stock options with a multi-year vesting schedule is a standard component of executive compensation packages across the life sciences and diagnostics industry, comparable to practices at companies like Danaher Corporation (DHR) or Thermo Fisher Scientific Inc. (TMO), aiming to incentivize long-term performance and retention.

Stakeholder Impact

• Shareholders: Interests are aligned with the CFO's long-term performance incentives.
• Employees: Standard executive compensation practices may set a precedent or reflect overall compensation philosophy.

Next Steps

• The options will vest over the next three years, with full vesting on August 15, 2028.
• The options can be exercised at any time after vesting until their expiration on August 15, 2032.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a key executive as part of their compensation package. While it aligns management incentives with shareholder interests, it does not present new information that would significantly alter the fundamental investment thesis for Revvity, Inc. Therefore, a 'hold' recommendation is appropriate as this filing alone does not warrant a change in investment strategy.

Keywords

Revvity, RVTY, stock options, executive compensation, insider transaction, Maxwell Krakowiak, Form 4